1. Home
  2. TPCS vs INTS Comparison

TPCS vs INTS Comparison

Compare TPCS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechPrecision Corporation

TPCS

TechPrecision Corporation

HOLD

Current Price

$4.95

Market Cap

40.9M

Sector

Industrials

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$0.37

Market Cap

24.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPCS
INTS
Founded
1956
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
24.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
TPCS
INTS
Price
$4.95
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$2.25
AVG Volume (30 Days)
32.5K
1.3M
Earning Date
11-13-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$33,564,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.15
N/A
52 Week Low
$2.05
$0.19
52 Week High
$6.25
$2.56

Technical Indicators

Market Signals
Indicator
TPCS
INTS
Relative Strength Index (RSI) 54.00 39.79
Support Level $4.75 $0.37
Resistance Level $5.03 $0.41
Average True Range (ATR) 0.24 0.02
MACD -0.02 -0.00
Stochastic Oscillator 33.77 9.22

Price Performance

Historical Comparison
TPCS
INTS

About TPCS TechPrecision Corporation

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: